Researchers reported “high efficacy and an excellent safety profile” for direct-acting antiviral (DAA) combinations with daclatasvir (DCV) among transplanted patients with hepatitis C virus (HCV) infection.
Sofosbuvir-based regimens “offer new therapeutic options” for patients with GT4 chroninc hepatitis C virus infection.
The EBR/GZR+SOF±RBV regimen is offers “high efficacy” in treating patients with GT3 Hepatitis C Virus (HCV).
Data from a retrospective cohort study presented at The Liver Meeting® 2016 has shown that hepatitis C virus (HCV)-infected patients with advanced chronic kidney disease (CKD) “remains a challenging population to treat,” with <10% receiving treatment in the early direct-acting antivirals (DAA) era.
Treatment with single tablet sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks “is a highly effective salvage therapy” for patients who did not previously achieve sustained virologic response (SVR) following treatment with non-NS5A inhibitor-containing direct-acting antivirals (DAAs), results from the POLARIS-4 study presented at The Liver Meeting® 2016 have shown.
A fixed-dose combination of pangenotypic direct-acting antivirals was “highly effective” in treatment-naïve patients with hepatitis C virus (HCV) genotypes (GT) 1, 2, and 3
3-DAA ± ribavirin achieved high 12-week sustained virologic response rates in Brazilian patients with GT1 hepatitis C virus (HCV) with bridging fibrosis or compensated cirrhosis.
No clinically significant changes in heart rate or cardiac adverse events were observed in patients with hepatitis C virus (HCV) infection on beta blockers receiving sofosbuvir (SOF)-based regimens, results of a study presented at The Liver Meeting® have found.
Among patients with liver cirrhosis, opioids are associated with increased mortality.
The all-oral, ribavirin-free glecaprevir/pibrentasvir regimen achieved high SVR12 rates in non-cirrhotic patients with hepatitis C virus (HCV) genotype (GT) 4, 5, and 6 infection, the phase 3 ENDURANCE-4 study concluded at The Liver Meeting® 2016.
